Compare INUV & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INUV | MDXH |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 21.1M |
| IPO Year | 1996 | 2021 |
| Metric | INUV | MDXH |
|---|---|---|
| Price | $0.96 | $0.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $11.00 | $7.67 |
| AVG Volume (30 Days) | 293.8K | ★ 606.9K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $86,209,305.00 | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | $12.89 | $18.31 |
| P/E Ratio | $8.00 | ★ N/A |
| Revenue Growth | ★ 2.88 | N/A |
| 52 Week Low | $0.95 | $0.40 |
| 52 Week High | $5.63 | $5.33 |
| Indicator | INUV | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 31.47 |
| Support Level | N/A | N/A |
| Resistance Level | $1.37 | $3.79 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 6.05 | 5.41 |
Inuvo Inc is an advertising technology and services company that has developed and commercialized large language generative artificial intelligence (AI) for modeling media audiences. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.